CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups

Cover Page

Cite item

Full Text

Abstract

Aim. Find the prevalence of CYP2C8*3 (rs10509681; rs11572080), PTGS-1 (rs10306135; rs12353214) and PTGS-2 (rs20417) alleles and genotypes in four ethnic groups among Laks, Avars, Dargins and Kumyks.

Materials and methods. The study involved 400 volunteers from four ethnic groups living in Republic of Dagestan: 100 participants from each group. Carriage of polymorphic markers was determined by reverse transcription polymerase chain reaction.

Results. Minor allele frequency of the CYP2C8 (rs10509681) was 5.5% in Avars, 10% in Dargins, Laks and Kumyks – 6.5% both; CYP2C8 (rs11572080) was 5.5% in Avars, 9.5% in Dargins, 6.5% in Laks, 8.5% in Kumyks; PTGS-1 (rs10306135) in Avars – 10.5%, in Dargins – 13.0%, in Laks – 9.5% and Kumyks – 7.5%; PTGS-1 (rs12353214) in Avars – 9.0%, in Dargins – 4.5%, in Laks – 7.5%, in Kumyks – 8.0%; PTGS-2 (rs20417) in Avars – 1.0%, in Dargins – 2.5%, in Laks – 3.5%, in Kumyks – 5.0%. There were no significant differences between groups.

Conclusion. The study of CYP2C8 and PTGS-1 and 2 gene polymorphisms is promising for predicting the effectiveness and safety of non-steroidal anti-inflammatory drug therapy, due to the high prevalence of these polymorphisms in ethnic groups in the North Caucasus.

About the authors

Sherzod P. Abdullaev

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0001-9001-1499

канд. биол. наук, зав. отд. молекулярой медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Natalia P. Denisenko

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0003-3278-5941

канд. мед. наук, зав. отд. персонализированной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Karin B. Mirzaev

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0002-9307-4994

канд. мед. наук, зав. лаб. Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Gregorii N. Shuev

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: abdullaevsp@gmail.com
ORCID iD: 0000-0002-5031-0088

мл. науч. сотр. отд. персонализированной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Zhannet A. Sozaeva

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0001-5166-7903

мл. науч. сотр. отд. молекулярной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Anastasia A. Kachanova

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0003-3194-4410

мл. науч. сотр. отд. молекулярной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Suleiman N. Mammaev

Dagestan State Medical University

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0001-8898-8831

д-р мед. наук, проф., зав. каф. госпитальной терапии №1 ФГБОУ ВО ДГМУ

Russian Federation, Makhachkala

Elvira A. Kasaeva

Dagestan State Medical University

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0003-0234-0597

канд. мед. наук, ассистент каф. госпитальной терапии №1, ФГБОУ ВО ДГМУ

Russian Federation, Makhachkala

Danial M. Gafurov

Republican Cardiological Dispensary

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0002-8321-9176

врач ГБУ РД РКД

Russian Federation, Makhachkala

Elena A. Grishina

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0002-5621-8266

д-р биол. наук, доц., дир. Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

Dmitry A. Sychev

Russian Medical Academy of Continuous Professional Education

Email: abdullaevsp@gmail.com
ORCID iD: 0000-0002-4496-3680

чл.-кор. РАН, проф. РАН, д-р мед. наук, проф., ректор ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

References

  1. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs. 2004;64(23):2619-27. doi: 10.2165/00003495-200464230-00001
  2. Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). 2021. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547742/ Accessed: 04.05.2021.
  3. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018;9(1):143-50. doi: 10.14336/AD.2017.0306
  4. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29 [Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29 (in Russian)]. doi: 10.14412/1995-4484-2018-1-29
  5. Agúndez JA, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009;5(6):607-20. doi: 10.1517/17425250902970998
  6. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 2010;278(2):165-88. doi: 10.1016/j.tox.2009.08.013
  7. Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi: 10.1002/cpt.1830
  8. Tracy TS, Marra C, Wrighton SA, et al. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8. doi: 10.1007/s002280050293
  9. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997;32(4):268-93. doi: 10.2165/00003088-199732040-00002
  10. Zajic SC, Jarvis JP, Zhang P, et al. Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative. Pharmacogenet Genomics. 2019;29(3):49-57. doi: 10.1097/FPC.0000000000000364
  11. Karaźniewicz-Łada M, Luczak M, Główka F. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica. 2009;39(6):476-85. doi: 10.1080/00498250902862705
  12. López-Rodríguez R, Novalbos J, Gallego-Sandín S, et al. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res. 2008;58(1):77-84. doi: 10.1016/j.phrs.2008.07.004
  13. García-Martín E, Martínez C, Tabarés B, et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004;76(2):119-27. doi: 10.1016/j.clpt.2004.04.006
  14. Kirchheiner J, Meineke I, Freytag G, et al. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther. 2002;72(1):62-75. doi: 10.1067/mcp.2002.125726
  15. Martínez C, García-Martín E, Blanco G, et al. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2005;59(1):62-9. doi: 10.1111/j.1365-2125.2004.02183.x
  16. Dorado P, Cavaco I, Cáceres MC, et al. A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol. 2008;64(10):967-70. doi: 10.1007/s00228-008-0508-4
  17. Lazarska KE, Dekker SJ, Vermeulen NPE, Commandeur JNM. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett. 2018;284:70-8. doi: 10.1016/j.toxlet.2017.11.038
  18. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272-81. doi: 10.1053/j.gastro.2006.11.023
  19. Cao L, Zhang Z, Sun W, et al. Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin. Gene. 2014;546(2):172-6. doi: 10.1016/j.gene.2014.06.023
  20. Sharma V, Kaul S, Al-Hazzani A, et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis. 2013;35(1):95-9. doi: 10.1007/s11239-012-0777-8
  21. Lee YS, Kim H, Wu TX, et al. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther. 2006;79(5):407-18. doi: 10.1016/j.clpt.2006.01.013
  22. Caciagli L, Bulayeva K, Bulayev O, et al. The key role of patrilineal inheritance in shaping the genetic variation of Dagestan highlanders. J Hum Genet. 2009;54(12):689-94. doi: 10.1038/jhg.2009.94
  23. Yunusbayev B, Metspalu M, Järve M, et al. The Caucasus as an asymmetric semipermeable barrier to ancient human migrations. Mol Biol Evol. 2012;29(1):359-65. doi: 10.1093/molbev/msr221
  24. Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019;20(11):847-65. doi: 10.2217/pgs-2019-0013
  25. Ромодановский Д.П., Хапаев Б.А., Игнатьев И.В., и др. Частоты «медленных» аллельных вариантов генов, кодирующих изоферменты цитохрома Р450 CYP2D6, CYP2C19, CYP2C9 у карачаевцев и черкесов. Биомедицина. 2010;1(2):33-7 [Romodanovskij DP, Hapaev BA, Ignatev IV, et al. Frequencies of “slow” allelic variants of genes encoding cytochrome P450 isoenzymes CYP2D6, CYP2C19, CYP2C9 in Karachais and Circassians. Biomedicine. 2010;1(2):33-7 (in Russian)].
  26. Батурин В.А., Царукян А.А., Колодийчук Е.В. Исследование полиморфизма гена CYP2C9 в этнических группах населения Ставропольского края. Медицинский вестник Северного Кавказа. 2014;9(1):45-8 [Baturin VA, Carukyan AA, Kolodijchuk EV. Study of CYP2C9 gene polymorphism in ethnic groups of Stavropol Krai. Medical Bulletin of the North Caucasus. 2014;9(1):45-8 (in Russian)]. doi: 10.14300/mnnc.2014.09013
  27. Sychev DA, Abdullaev SP, Mirzaev KB, et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019;46(3):2761-69. doi: 10.1007/s11033-019-04722-w
  28. Mirzaev KB, Sychev DA, Ryzhikova KA, et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genet Test Mol Biomarkers. 2017;21(12):747-53. doi: 10.1089/gtmb.2017.0036
  29. Tang H, Quertermous T, Rodriguez B, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005;76(2):268-75. doi: 10.1086/427888
  30. The ALlele FREquency Database. Available at: https://alfred.med.yale.edu/alfred/index.asp. Accessed: 10.05.2021.
  31. GnomAD Exome. Available at: https://gnomad.broadinstitute.org/ Accessed: 10.05.2021.
  32. Karafet TM, Bulayeva KB, Bulayev OA, et al. Extensive genome-wide autozygosity in the population isolates of Daghestan. Eur J Hum Genet. 2015;23(10):1405-12. doi: 10.1038/ejhg.2014.299

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies